When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

By Akin Nazli in Belgrade Ugur Sahin, owner of BioNTech (Nasdaq/BNTX), has been ranked second in Forbes Turkey’s Top 100 ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Despite a net loss, BioNTech SE (BNTX) remains focused on oncology advancements and maintains a strong financial position ...

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming ...

May 5, 2025 BioNTech says Novartis executive Zapata-Gomez to become CFO German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

This was compounded by an analyst's price target cut for the German biotech. When the smoke cleared, BioNTech's shares closed the day more than 6% lower. That was a more dramatic slide than the 0. ...